Artios Pharma to Present at the 43rd Annual J.P. Morgan Healthcare Conference
CAMBRIDGE, United Kingdom and NEW YORK, December 19, 2024 – Artios Pharma Limited (“Artios”), a clinical-stage biotech company led by...
DNA
Rakovina Therapeutics: Reflecting on 2024 Success and Building Momentum for a Transformative 2025
VANCOUVER, British Columbia, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (“Rakovina” or the “Company”) (TSX-V: RKV) a biopharmaceutical...
Nurix Therapeutics Receives U.S. FDA Fast Track Designation for NX-5948 for the Treatment of Relapsed or Refractory Waldenstrom’s Macroglobulinemia
Fast track designation follows positive Phase 1 data presented at the 12th International Workshop on Waldenstrom’s MacroglobulinemiaSAN FRANCISCO, Dec. 19,...
Bio-Path Holdings Announces Preclinical Testing of BP1001-A as Potential Treatment for Obesity in Type 2 Diabetes Patients Enhances Insulin Sensitivity
Preclinical Studies Confirmed BP1001-A Mechanism of Action and Therapeutic Potential in Obesity and Type 2 DiabetesHOUSTON, Dec. 19, 2024 (GLOBE...
Lab Automation Market to Hit USD 7.71 Billion by 2029 with 6.9% CAGR | MarketsandMarkets™
DELRAY BEACH, Fla., Dec. 18, 2024 /PRNewswire/ -- The global lab automation market is expected to reach USD 7.71 Billion by...
DNAnexus Recognized by Frost & Sullivan for Ability to Integrate and Synchronize Diverse Clinical and Multi-omics Data
Leading cloud-based enterprise platform for precision health data empowers biopharma companies with actionable insights to accelerate drug discovery and development SAN ANTONIO,...
Applied DNA Customer ÚHKT Initiates Phase I Clinical Trial for Rapidly Manufacturable CAR T-Cell Therapy Produced from Linea DNA
- Regulatory Approval Showcases Clinical Advancement of Linea DNA™ as a Rapid and Effective Means of Producing CAR-T cell Therapies...
Neutrolis Expands Senior Leadership Team to Drive Development of Growing Pipeline of Non-Immunosuppressive Therapies for NET-mediated Autoimmune Diseases
Appointment of seasoned executives with substantial industry expertise strengthens team as the company advances programs into the clinicCAMBRIDGE, Mass., Dec....
Tessera Therapeutics Receives Investment to Develop Curative In Vivo Genetic Treatment for Sickle Cell Disease
Investments of up to $50 million from the Bill & Melinda Gates Foundation to develop globally accessible in vivo genetic...
Applied DNA Announces Fourth Quarter and Fiscal Year 2024 Financial Results, Announces Strategic Restructuring to Prioritize the Manufacture of Critical Starting Materials for Genetic Medicines
- Pursuing Divestiture of CertainT® Platform, Implements Changes to Corporate Leadership -- Build-out of GMP Manufacturing Facility to be Completed...
March of Dimes Awards Dr. Dennis Lo the 2025 March of Dimes Richard B. Johnston, Jr., MD Prize
Recognized for discovery of cell-free fetal DNA in maternal blood and creation of noninvasive prenatal testing (NIPT), used by as...
TruDiagnostic Introduces Revolutionary Epigenetic Biomarker Proxies: New Diagnostic Approach Outperforms Traditional Lab Results
LEXINGTON, Ky., Dec. 17, 2024 /PRNewswire/ -- TruDiagnostic, a global leader in advanced epigenetic research, proudly announces a groundbreaking advancement in...
Ginkgo Bioworks Awarded $9.4 Million in Partnership with Carnegie Mellon University to Develop Implantable Cell-Based Bioelectronic Devices for Disease Treatment Under ARPA-H’s REACT Program
Ginkgo Bioworks to apply its mammalian cell engineering expertise to develop new cell-based systems for treating and monitoring endocrine disorders...
Alira Health Secures Up to $100M Growth Debt Facility from Symbiotic Capital to Propel Strategic Expansion and Patient-Enabled Innovation
FRAMINGHAM, Mass., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Alira Health, a global healthcare consulting and technology firm transforming the patient...
Actuate Therapeutics Announces Positive Interim Phase 2 Data of Elraglusib in First Line Treatment of Metastatic Pancreatic Cancer
Statistical Significance Met on Primary Endpoints of 1 Year Survival Rate and Median Overall SurvivalDoubling of 1 Year Survival Rate...
Immutep Announces Initial Safety Data from First-in-Human Phase I Trial Evaluating IMP761
Favourable safety profile for world’s first LAG-3 agonist, IMP761, with no treatment related adverse events to dateAdditional safety data and...
Actuate Therapeutics Announces Positive Interim Phase 2 Data of Elraglusib in First Line Treatment of Metastatic Pancreatic Cancer
Statistical Significance Met on Primary Endpoints of 1 Year Survival Rate and Median Overall SurvivalDoubling of 1 Year Survival Rate...
BioCardia Announces Commercial Availability of Morph® DNA™ Steerable Introducer Product Family
SUNNYVALE, Calif., Dec. 17, 2024 (GLOBE NEWSWIRE) -- BioCardia, Inc. , a global leader in cellular and cell-derived therapeutics for the...
Tenaya Therapeutics Reports Promising Early Data from MyPEAK™-1 Phase 1b/2 Clinical Trial of TN-201 for Treatment of MYBPC3-Associated Hypertrophic Cardiomyopathy
TN-201 Well Tolerated at 3E13 vg/kg Dose AAV9 Capsid Demonstrated Robust Delivery of TN-201 Transgene to Heart Muscle Cells Resulting...
CellarisBio Announces “CHALLENGING TARGET AWARD” to Promote Innovation in Drug Discovery
SAN DIEGO, Dec. 16, 2024 /PRNewswire/ -- CellarisBio breaks ground with an announcement of "Challenging Target Award" to foster innovation...